India, Japan Shake Hands For Faster Entry Of Generics But Market Realities May Be Tougher To Handle
This article was originally published in PharmAsia News
MUMBAI/TOKYO - Introduction of non-discriminatory or national treatment clauses for Indian generic companies in the latest trade agreement between India and Japan will facilitate wider access for Indian generic firms to the world's second-largest pharma market, but analysts predict headwinds await before companies get a real bang for their buck
You may also be interested in...
In search of business opportunities, several Indian and Japanese drug makers have come under one roof to identify joint projects. The architect of the new initiative is Satish Khanna, an industry veteran who has seen successes with similar ventures in the past.
A high-profile joint venture between Fujifilm and Dr. Reddy’s to sell generic drugs in Japan has been terminated only two years after an initial MOU.
Disputes over EU blockades of Indian drug shipments are still on the negotiation table, says Commerce Ministry. India hopes to initiate talks with China as well.